Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
GlycoMimetics, Inc. - Common Stock
(NQ:
GLYC
)
0.2339
+0.0284 (+13.82%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,034,882
Open
0.2000
Bid (Size)
0.2200 (39)
Ask (Size)
0.2399 (1)
Prev. Close
0.2055
Today's Range
0.2000 - 0.2474
52wk Range
0.1406 - 3.530
Shares Outstanding
64,483,958
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
November 06, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC
October 31, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Performance
YTD
-91.40%
-91.40%
1 Month
-26.91%
-26.91%
3 Month
+42.19%
+42.19%
6 Month
-12.27%
-12.27%
1 Year
-90.79%
-90.79%
More News
Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 30, 2024
Via
Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
October 30, 2024
Via
Benzinga
Why GlycoMimetics Stock is Trading Higher Monday
June 25, 2024
Via
Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders
October 29, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Profire Energy, Inc. (Nasdaq – PFIE), Cepton, Inc. (Nasdaq – CPTN), GlycoMimetics, Inc. (Nasdaq – GLYC), ARC Document Solutions, Inc. (NYSE - ARC)
October 29, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results
October 29, 2024
Via
Benzinga
GlycoMimetics Shares Are Soaring Tuesday: Here's Why
October 29, 2024
Via
Benzinga
Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views
October 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 29, 2024
Via
Benzinga
Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders
October 29, 2024
From
Ademi LLP
Via
Business Wire
US Stocks Mixed; McDonald's Posts Upbeat Earnings
October 29, 2024
Via
Benzinga
GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders
October 29, 2024
From
Halper Sadeh LLC
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 29, 2024
Via
Benzinga
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
October 29, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
October 29, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
July 25, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
7 Sorry Biotech Stocks Set to Make Investors Sad
July 22, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
June 26, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 25, 2024
Via
InvestorPlace
$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
June 21, 2024
Via
Benzinga
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
June 04, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
May 29, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.